glp 1 agonists microdose Microdosing of GLP-1's / Wellness Services / Services Microdosing GLP-1 Drugs: What To

Dose reduction of concomitant medications is typically required when initiating GLP-1 or dual-agonist therapy

PMID 15090972

A meta-analysis of clinical studies indicated that treatment with GLP-1RAs of obese patients with T2MD did not increase the risk of breast tumors, nor did it increase the risk of acute pancreatitis, pancreatic cancer, and overall tumor neoplasia (207209)

Compounded versions are not FDA-approved and have not undergone clinical trials

Gejl M, Gjedde A, Egefjord L, Moller A, Hansen SB, Vang K, et al

Growing evidence supports the positive impact of GLP-1 RAs in reducing hepatic cytolysis enzymes [56,61,69,70,71,72,73,74,75,76,77,78,79,80,81] (Table 2)